X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-11-21 | MDGL | Huntsman Carole | Chief Commercial Officer | S - Sale | $316.92 | -688 | 10,785 | -6% | -$218,041 | ||||||
| D | 2024-11-07 | MDGL | Levy Richard S | Dir | S - Sale+OE | $350.00 | -5,000 | 11,012 | -31% | -$1,750,000 | |||||
| D | 2024-11-01 | MDGL | Levy Richard S | Dir | S - Sale+OE | $300.94 | -5,000 | 11,012 | -31% | -$1,504,703 | |||||
2024-09-09 | MDGL | Sibold William John | Pres, CEO | S - Sale | $243.83 | -6,363 | 55,887 | -10% | -$1,551,490 | ||||||
| D | 2024-06-14 | MDGL | Waltermire Robert E. | SVP, Chief Pharma Dev. | S - Sale+OE | $280.00 | -1,900 | 5,500 | -26% | -$532,000 | |||||
| D | 2024-06-12 | MDGL | Waltermire Robert E. | SVP, Chief Pharma Dev. | S - Sale+OE | $285.00 | -2,000 | 5,500 | -27% | -$570,000 | |||||
2024-05-21 | MDGL | Waltermire Robert E. | SVP, Chief Pharma Dev. | S - Sale | $231.34 | -1,036 | 5,500 | -16% | -$239,668 | ||||||
| D | 2024-05-14 | MDGL | Craves Fred B | Dir | S - Sale+OE | $212.88 | -22,489 | 489,685 | -4% | -$4,787,404 | |||||
| D | 2024-04-08 | MDGL | Taub Rebecca | Pres, R, D,, CMO | S - Sale+OE | $245.99 | -2,676 | 1,114,539 | 0% | -$658,258 | |||||
| D | 2024-04-08 | MDGL | Friedman Paul A | Dir | S - Sale+OE | $246.19 | -26,270 | 841,275 | -3% | -$6,467,491 | |||||
| DM | 2024-04-03 | MDGL | Taub Rebecca | Pres, R, D,, CMO | S - Sale+OE | $243.92 | -73,888 | 1,114,539 | -6% | -$18,022,588 | |||||
| DM | 2024-04-03 | MDGL | Friedman Paul A | Dir | S - Sale+OE | $243.93 | -73,730 | 841,275 | -8% | -$17,984,804 | |||||
| D | 2024-04-01 | MDGL | Levy Richard S | Dir | S - Sale+OE | $257.49 | -11,000 | 10,298 | -52% | -$2,832,335 | |||||
| DM | 2024-04-01 | MDGL | Bate Kenneth | Dir | S - Sale+OE | $252.86 | -32,489 | 1,198 | -96% | -$8,214,998 | |||||
| DM | 2024-04-01 | MDGL | Daly James M | Dir | S - Sale+OE | $252.97 | -32,489 | 1,198 | -96% | -$8,218,630 | |||||
| DM | 2023-12-14 | MDGL | Waltermire Robert E. | SVP, Chief Pharma Dev. | S - Sale+OE | $235.50 | -4,000 | 5,667 | -41% | -$942,000 | |||||
| M | 2023-12-13 | MDGL | Baker Bros. Advisors LP | Dir | P - Purchase | $221.20 | +101,792 | 1,793,403 | +6% | +$22,516,577 | |||||
2023-12-12 | MDGL | Baker Bros. Advisors LP | Dir | P - Purchase | $218.31 | +34,578 | 1,699,129 | +2% | +$7,548,616 | ||||||
| DM | 2023-12-12 | MDGL | Waltermire Robert E. | SVP, Chief Pharma Dev. | S - Sale+OE | $222.82 | -3,800 | 5,667 | -40% | -$846,700 | |||||
| DM | 2023-12-04 | MDGL | Lynch Brian Joseph | SVP, GC | S - Sale+OE | $221.89 | -2,800 | 15,531 | -15% | -$621,294 | |||||
| DM | 2023-11-29 | MDGL | Lynch Brian Joseph | SVP, GC | S - Sale+OE | $201.50 | -7,000 | 15,531 | -31% | -$1,410,480 | |||||
2023-11-21 | MDGL | Baker Bros. Advisors LP | Dir | P - Purchase | $188.48 | +64,350 | 1,667,104 | +4% | +$12,128,340 | ||||||
| M | 2023-11-17 | MDGL | Baker Bros. Advisors LP | Dir | P - Purchase | $178.11 | +67,079 | 1,607,668 | +4% | +$11,947,280 | |||||
| M | 2023-11-14 | MDGL | Baker Bros. Advisors LP | Dir | P - Purchase | $158.13 | +49,387 | 1,545,775 | +3% | +$7,809,559 | |||||
| M | 2023-11-13 | MDGL | Baker Bros. Advisors LP | Dir | P - Purchase | $146.99 | +107,499 | 1,500,227 | +8% | +$15,801,021 | |||||
| DM | 2023-02-28 | MDGL | Waltermire Robert E. | SVP, Chief Pharma Dev. | S - Sale+OE | $273.24 | -10,000 | 5,667 | -64% | -$2,732,438 | |||||
| D | 2023-01-17 | MDGL | Levy Richard S | Dir | S - Sale+OE | $293.15 | -22,489 | 9,100 | -71% | -$6,592,686 | |||||
| D | 2023-01-03 | MDGL | Lynch Brian Joseph | SVP, GC | S - Sale+OE | $282.92 | -13,000 | 530 | -96% | -$3,677,977 | |||||
| D | 2022-12-23 | MDGL | Lynch Brian Joseph | SVP, GC | S - Sale+OE | $274.18 | -7,000 | 530 | -93% | -$1,919,231 | |||||
| D | 2022-12-23 | MDGL | Sukhija Remy | Chief Commercial Officer | S - Sale+OE | $274.14 | -30,000 | 0 | -100% | -$8,224,073 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |